Eli Lilly (LLY) has recently seen both ups and downs in the market. Notable events include LLY's Q3 financial results, which posted strong revenue growth from new products, but fell short of Wall Street expectations. The company's stock has fallen over 20% from its high, leading many to speculate whether it is the right time to buy. Particularly important is the news that LLY has received a rating upgrade, with some suggesting that it is an 'Early Christmas Present.' Most recently, President Biden's proposal for Medicare to cover obesity drugs has caused a surge in the stock. The company also recently announced a significant $4.5 billion investment in creating the 'Lilly Medicine Foundry,' a site dedicated to drive innovation in drug production and making medicines for clinical trials. Despite this, the company also saw a rare sales miss for their weight-loss drug. Other noteworthy news includes the announcement of LLY's Q2 2024 financial results, and the proposed acquisition of Morphic to improve outcomes for patients with Inflammatory Bowel Disease.
Eli Lilly LLY News Analytics from Mon, 24 Jun 2024 15:35:17 GMT to Sat, 30 Nov 2024 12:00:00 GMT -
Rating -2
- Innovation 8
- Information 6
- Rumor -6
